BeOne Medicines Ltd. (ONC) Institutional Ownership & Insider Trading

279 institutions reported holding BeOne Medicines Ltd. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 207 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

ONCBeOne Medicines Ltd.Follow ONC — free

Drug Manufacturers - General · Healthcare

—

Price chart with a free account

Market cap: 42.9B
P/E TTM: 67.6
Dividend yield: —
52-week: —
Next earnings: 5 Nov, in 12 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

279 institutions held 2.4% of the shares. Across filers that reported both quarters, shares held changed +0.1%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	279	35	+0.1%	109	34	63	32
Mar 26	278	35	+2.8%	106	27	77	29
Dec 25	279	34	+2.3%	104	41	69	30
Sep 25	254	33	-4.4%	76	53	70	34
Jun 25	240	34	-18.8%	83	24	75	39
Mar 25	258	42	-2.5%	76	59	72	22
Dec 24	222	44	-5.1%	72	25	70	27
Sep 24	221	46	-1.5%	45	49	77	22

BeOne Medicines Ltd. — questions

Who owns BeOne Medicines Ltd. stock?: 279 institutions reported BeOne Medicines Ltd. shares in 13F filings for the quarter ended 2026-06-30. The largest: BAKER BROS. ADVISORS LP (0.6%), PRIMECAP MANAGEMENT CO/CA/ (0.3%), Capital International Investors (0.3%).
Are BeOne Medicines Ltd. insiders buying or selling?: 207 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from BeOne Medicines Ltd.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.